190 related articles for article (PubMed ID: 38282415)
21. Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
Cheung AM; Wang D; Liu K; Hope T; Murray M; Ginty F; Nofech-Mozes S; Martel AL; Yaffe MJ
Breast Cancer Res; 2021 Dec; 23(1):114. PubMed ID: 34922607
[TBL] [Abstract][Full Text] [Related]
22. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
23. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
24. Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system.
Wafai R; Williams ED; de Souza E; Simpson PT; McCart Reed AE; Kutasovic JR; Waltham M; Snell CE; Blick T; Thompson EW; Hugo HJ
Breast Cancer Res; 2020 Dec; 22(1):136. PubMed ID: 33276802
[TBL] [Abstract][Full Text] [Related]
25. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
Althobiti M; El-Sharawy KA; Joseph C; Aleskandarany M; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Oct; 189(3):621-630. PubMed ID: 34453638
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
27. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer.
Manning DL; McClelland RA; Gee JM; Chan CM; Green CD; Blamey RW; Nicholson RI
Eur J Cancer; 1993; 29A(10):1462-8. PubMed ID: 8398276
[TBL] [Abstract][Full Text] [Related]
28. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
[TBL] [Abstract][Full Text] [Related]
29. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
30. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
31. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
32. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
33. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
34. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
Niikura N; Iwamoto T; Masuda S; Kumaki N; Xiaoyan T; Shirane M; Mori K; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Cancer Sci; 2012 Aug; 103(8):1508-12. PubMed ID: 22537114
[TBL] [Abstract][Full Text] [Related]
36. ER-/PR+/HER2- breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases.
Arena V; Pennacchia I; Vecchio FM; Carbone A
Breast J; 2019 May; 25(3):381-385. PubMed ID: 30916428
[TBL] [Abstract][Full Text] [Related]
37. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
40. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]